2:15PM 11/13/2014 – 10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston
Reporter: Aviva Lev-Ari, PhD, RN
REAL TIME Coverage of this Conference by Dr. Aviva Lev-Ari, PhD, RN – Director and Founder of LEADERS in PHARMACEUTICAL BUSINESS INTELLIGENCE, Boston http://pharmaceuticalintelligence.com
2:15 p.m. Panel Discussion Reimbursement/Regulation
Moderator:
Sheila D. Walcoff, J.D.
CEO and Founder, Goldbug Strategies, LLC
Panelists:
2. Catalina Lopez Correa, M.D., Ph.D.
Vice President/CSO, Scientific Affairs
Génome Québec
1. Michael Kolodziej, M.D.
National Medical Director for Oncology Strategies, Aetna
Clinical Utility Test is done cheap the drug used as therapeutics is $10,000 – without knowing if it will work or not
3. Bruce Quinn, M.D., Ph.D.
Senior Health Policy Specialist
Foley Hoag LLP
It is a whole ecosystem,
1. CMS – ACA
2. On diagnostics: clinical utility (six questions), clinical validity, analytical
$50 test kit from Abbott, 20,000 patients – $1 million market for test, Drug: $100,000 = $1 Billion for Pharma
- If Patient sign Risks are known, Physician is educated, Patient is educated by Physician
- Participation in Registry — test is covered
- making information actionable to the Consumer
See more at: http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.qGbGZXXf.dpuf
@Aetna (for Dr. Kolodziej)
@FoleyHoag (for Bruce Quinn)
Leave a Reply